Developing highly targeted PROTAC molecules to attack cancers, as well as viral and autoimmune diseases.
Envisioning better outcomes for patients and their families.
What We Do
Our team of scientists is working tirelessly to develop a novel class of high-potency, low-toxicity, targeted therapeutic agents termed “degraders” for undruggable targets.
Therabene’s proprietary molecules are designed for the treatment of cancers, autoimmune diseases, certain types of viral infections, and other difficult-to-treat diseases that harm patients and their families.
Traditional drug discovery has focused on controlling protein activity. At Therabene, we are reaching far beyond that boundary using degraders as a novel therapeutic modality.
We are developing a novel class of high-potency, low-toxicity, targeted therapeutic agents.
In preclinical development for pancreatic cancer
In preclinical development for triple-negative breast cancer
Dr. Mario DiPaola
Dr. Mario DiPaola is an experienced executive with a 25-year record in the biotechnology and pharmaceutical industries. He is also the founder of Oncovolution, a next-generation, platinum-based chemotherapies company.
DiPaola founded and led Blue Stream Laboratories, which developed complex biologics and biosimilars. When the company was acquired by Charles River Laboratories in 2016, DiPaola stayed on, provided scientific guidance to the Biologics Division, and established a large molecule formulation laboratory.
DiPaola has extensive experience in basic research, development, quality, manufacturing, and regulatory functions for protein and small molecule development. He has served in various positions with companies such as Antigenics, Biogen, CuriRx, Tektagen, and Interferon Sciences. He has participated in the development and regulatory filings for several approved therapeutics.
DiPaola has authored or co-authored more than sixty publications, was an associate research professor at Columbia University, and is credited as a co-inventor in four patents. He received his PhD in chemistry and biochemistry from New York University, an MBA in finance from Baruch College, CUNY, and is a member of the Beta Delta Chi Honor Society. He has held prestigious fellowships at Columbia University and New York University.
“Big results require big ambitions.”
- Heraclitus -
Therabene is actively seeking partnerships to advance the development of our PROTAC molecules. We partner with academic and clinical research institutions and pharmaceutical, biopharma, and biotech companies on specific assets and disease states.